Opinion|Videos|June 10, 2024
Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches
Vijayakrishna Gadi, MD, PhD, presents the case of a 54-year-old woman with HER2-positive metastatic breast cancer exhibiting bone, liver, and brain lesions, and key opinion leaders share their perspectives on the most appropriate treatment approaches tailored to the patient's specific disease characteristics and metastatic sites.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Patient Case: A 54-year-old woman with HER2+ metastatic breast cancer and brain metastases
- Please describe your initial impressions of this case. How might you have treated this patient in your practice?
- Per the NCCN guidelines, what is the preferred treatment approach for this patient/patients with systemic and CNS progression?
- In which lines of therapy do the NCCN guidelines recommend using the tucatinib + trastuzumab + capecitabine regimen for patients with brain metastases?
- Please discuss the differences between active and stable brain metastases and how these factors influence your treatment decisions.
- At what points during metastatic breast cancer treatment do you typically screen for brain metastases?
- How do you view the role of systemic therapy versus local therapy in the management of brain metastases in HER2-positive mBC?
Advertisement
Related to this article
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Obesity may increase breast cancer risk partly by removing a natural defense.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
China's NMPA Approves Pirtobrutinib Across CLL
4
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
5